IL5 and mastocytosis: Moreover, a human patient with eosinophilic asthma and an idiopathic mastocytosis receiving mepolozumab showed an eosinophil reduction and surprisingly a parallel significant reduction of mast cell-derived tryptase, strongly linked to mepolizumab applications, thus, further suggesting an eosinophil-mast cell interaction controlled by IL-5 [28].